abstract |
Use of hydroxyapatite (HA) and an alpha emission radionuclide chosen from the group of 211At, 212Bi, 223Ra, 224Ra, 225Ac, 227Th or a beta emission radionuclide chosen from the group of 212Pb, 211Pb, 213Bi or 225Ra in the manufacture of a medicine for use in the treatment of a cancerous disease |